The investment was led by Redmile Group with participation of additional new investors Invus and Samsara BioCapital, as well as a number of current investors.
The new funding will be primarily used to progress the clinical development of Hookipa's lead development programmes, HB-101, a prophylactic cytomegalovirus vaccine candidate, currently in a Phase 2 clinical trial in patients awaiting kidney transplantation as well as HB-201 and HB-202, the company's lead oncology product candidates, in development for the treatment of human papillomavirus-positive cancers.
In addition, Hookipa plans to apply its arenavirus platform to develop additional novel immuno-oncology product candidates.
Hookipa Pharma is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogramme the body's immune system.
Hookipa's proprietary arenavirus-based technologies, VaxWave, a replication-deficient viral vector, and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralising antibodies.
Both, VaxWave and TheraT, are designed to allow for repeat administration while maintaining an immune response.
TheraT has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. Hookipa's "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.
Hookipa has successfully completed a Phase 1 trial of a VaxWave-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
To expand its infectious disease portfolio, Hookipa has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections.
Hookipa is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma